AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent (English only)
- Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brain
- New grant funding will pave the way for enhanced clinical studies
- Total funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) awarded the Company a new grant to continue development of its Morphomer®-based alpha-synuclein (a-syn) positron emission tomography (PET) tracer, ACI-12589.